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Tumor hypoxia is associated with poor patient outcomes in estrogen
receptor-α–positive (ERα+) breast cancer. Hypoxia is known to affect
tumor growth by reprogramming metabolism and regulating amino
acid (AA) uptake. Here, we show that the glutamine transporter,
SNAT2, is the AA transporter most frequently induced by hypoxia
in breast cancer, and is regulated by hypoxia both in vitro and in vivo
in xenografts. SNAT2 induction in MCF7 cells was also regulated by
ERα, but it became predominantly a hypoxia-inducible factor 1α
(HIF-1α)–dependent gene under hypoxia. Relevant to this, binding
sites for both HIF-1α and ERα overlap in SNAT2’s cis-regulatory
elements. In addition, the down-regulation of SNAT2 by the ER
antagonist fulvestrant was reverted in hypoxia. Overexpression
of SNAT2 in vitro to recapitulate the levels induced by hypoxia
caused enhanced growth, particularly after ERα inhibition, in hypoxia,
or when glutamine levels were low. SNAT2 up-regulation in vivo
caused complete resistance to antiestrogen and, partially, anti-VEGF
therapies. Finally, high SNAT2 expression levels correlated with
hypoxia profiles and worse outcome in patients given antiestrogen
therapies. Our findings show a switch in the regulation of SNAT2
between ERα and HIF-1α, leading to endocrine resistance in hypoxia.
Development of drugs targeting SNAT2 may be of value for a subset
of hormone-resistant breast cancer.
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The estrogen receptor-α–positive (ERα
+) subtype accounts for
∼70% of all newly diagnosed cases of breast cancer in
Europe and the United States (1). The majority of these tumors
depend on estrogen signaling, thereby providing the rationale for
using antiestrogens as adjuvant therapy to treat breast cancer.
Endocrine agents targeting ERα, such as tamoxifen, fulvestrant,
or aromatase inhibitors, represent the cornerstone of systemic
treatment of this breast cancer subtype (2). However, despite
recent therapeutic advances, poor response and resistance limit
the effectiveness of these agents in up to 30% of patients (3).
Many mechanisms have been proposed to account for endocrine
resistance such as genetic (e.g., loss of ERα expression, mutation,
expression of truncated ER isoforms), activation by peptide growth
factors, and epigenetic (e.g., methylation, promoter inhibition)
changes within the tumor that activate hormone-independent
mitogenic pathways (4). In addition to cancer cell-autonomous
factors, the host microenvironment can contribute to endocrine
resistance (5). Hypoxia is a key microenvironmental difference
between tumor and normal tissues and is related to poor clinical
prognosis and resistance to therapies in many solid tumors, in-
cluding breast cancer (6). Indeed, hypoxia and increased expres-
sion of hypoxia-inducible factor 1α (HIF-1α), the key transcription
factor mediating hypoxia response, are associated with endocrine
resistance to neoadjuvant and adjuvant therapy in ERα+ breast
cancers (7–9). We recently found that the HIF-1α gene bears a
canonical ER-binding element that responds to estrogen signaling,
demonstrating a direct regulatory link between the ERα and HIF-
1α pathways in breast cancer (10). HIF-1α function could com-
pensate for estrogen signaling when ERα function is compromised
during hormone therapy, and thus cause resistance to tamoxifen
or fulvestrant treatment (10).
A crucial mechanism by which the growth of cancer cells is pro-
moted in hypoxic microenvironments is by metabolic reprogramming
(11). The adaptation to hypoxia is coordinated by HIF-1α, which
induces metabolic genes involved in increasing glycolytic flux (12).
There is also up-regulation of glutamine metabolism to support
proliferation, lipid biosynthesis, and protection from free radical
stress (13). In addition to pyruvate derived from glycolysis, hypoxic
cancer cells can supply substrates to the tricarboxylic acid (TCA)
cycle to sustain mitochondrial adenosine 5′-triphosphate (ATP)
production (anaplerosis) through the uptake of amino acids (AAs),
such as glutamine, glycine, and serine. In particular, glutamine can
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fuel the TCA cycle through a series of biochemical reactions termed
glutaminolysis (14).
This gives a strong rationale to identify hypoxia-induced metabolic
alterations, particularly regarding glutaminolysis. Several studies
have shown that endocrine therapy resistance in breast cancer cells is
modulated by metabolic rewiring and tamoxifen-resistant cells are
characterized by HIF-1α hyperactivation via modulation of Akt/
mammalian target of rapamycin (mTOR), thus resulting in enhanced
aerobic glycolysis and mitochondrial metabolism (15, 16). These
data highlight the importance of metabolic adaptability of cancer
cells for endocrine therapy resistance and suggest that targeting
glutamine metabolism could be a novel approach to overcome re-
sistance to endocrine therapies.
Because tumor cells under hypoxia have a high demand for AA,
we hypothesized that AA transporters may be up-regulated selectively
to meet this demand. Thus, we investigated the role of hypoxia-
regulated AA transporters and in endocrine therapy resistance.
Results
Identification of Hypoxia-Induced AA Transporters by RNA-Sequencing.
To define the AA transporters that are involved in hypoxic adaptation,
a panel of breast cancer cell lines was cultured in hypoxia (0.1% O2)
for 24 h and RNA-sequencing (RNA-seq) was then performed. This
panel included ER+ MCF7 and T47D; HER2+ SKBR3, BT474, and
ZR751; and triple receptor-negative cell lines MDA-MB-231, MDA-
MB-453, MDA-MB-468, BT20, and BT549. We analyzed trans-
membrane AA transporters expressed in tumors (17). As AAs are crucial
for maintenance of the TCA cycle throughout anaplerosis, we applied
in silico hierarchical clustering and supervised exploratory analysis to
evaluate which AA transporters promoting the uptake of specific
substrates in the TCA cycle might be crucial for maintaining anaplerotic
pathways in hypoxia. We assessed the substrates of these AA trans-
porters: glucogenic versus ketogenic AAs, essential versus nonessential
AAs, and the entry of their substrates into the TCA cycle.
Several AA transporters are up-regulated under hypoxia in breast
cancer cell lines (Dataset S1), but only three transporters among the
25 investigated are consistently up-regulated and clustered under hypoxia
in more than three cell lines. SLC1A1, SLC7A5 (LAT1), and SLC38A2
(SNAT2) transporters were coregulated in MCF7, T47D, SKBR3,
MDA-MB-231, MDA-MB-468, BT549, BT20, and BT474 (Fig. 1).
The branched-chained AA transporter LAT1 (SLC7A5) is a HIF-2α
target (18), while SLC1A1 is a glutamate HIF-dependent transporter
(19) (Fig. 1). The third AA transporter in the cluster strongly up-
regulated across a wide spectrum of cell lines under hypoxia is SNAT2,
which is involved in neutral AA intake (20). Theoretically, the AAs
provided by these three transporters could account for all AA precur-
sors of TCA cycle metabolites (SI Appendix, Fig. S1A). SLC7A5 can
support the uptake of ketogenic AAs, SLC1A1 the uptake of glutamate,
and SNAT2 the uptake of other neutral gluconeogenic AAs such as
glutamine, alanine, glycine, and serine. Validation of induction by
hypoxia by qPCR assay of these AA transporters was performed in
six different cell lines (SI Appendix, Fig. S1B). Further analysis of
RNA-seq data of four breast cancer cell lines with different receptor
phenotypes (MCF-7, SKBR3, MDA-MB-231, and MDA-MB-468)
Fig. 1. SLC38A2 (SNAT2), SLC7A5, and SLC1A1 are the hypoxic-induced AA transporters in breast cancer cell lines. Ten breast cancer cell lines (columns)
cultured in normoxia and hypoxia and submitted to RNA-seq were arranged by supervised average-linkage hierarchical clustering. Heatmap colors represent
relative mRNA expression of the selected AA transporters (rows), with higher (red) or lower (blue) expression in hypoxia compared with normoxia. AA
transporters that mediate the uptake of gluconeogenic (G) or ketogenic (KG) essential (E) or nonessential (NE) AAs that enter specific steps of the TCA cycle
(α-ketoglutarate, fumarate, oxaloacetate, and pyruvate) were clustered. The black box represents the cluster composed of three AA transporters (SLC1A1,
SLC7A5, and SLC38A2) in eight cell lines. S, semiessential; TRN, triple receptor-negative.






























demonstrated that, in addition to the full-length SNAT2 transcript
(isoform 1), there were truncated splice variants of SNAT2 (isoforms
2 and 3) encoding shorter proteins lacking three and six transmembrane
domains (SI Appendix, Fig. S1C). The three isoforms encode for pro-
teins (predicted by TMHMM Server) of 56, 45, and 38 kDa, respectively
(SI Appendix, Fig. S1D). A qPCR assay for specific amplification of only
the two main isoforms (1, 2) was used, as isoform 3 was not detected. In
the cell lines where SNAT2 was induced, there was an increase of ex-
pression of both SNAT2 messenger RNA (mRNA) isoforms 1 and
2 after 24 h of 0.1% O2 (SI Appendix, Fig. S1E).
SNAT2 Protein Is Up-Regulated Under Hypoxia In Vitro Mainly in a HIF-
1α–Dependent Manner. We examined SNAT2 protein expression
(Fig. 2A) using an antibody against SNAT2 isoform 1. Basal RNA
(SI Appendix, Fig. S2A) and protein and hypoxic SNAT2 induction
varied among cell lines. Measurement of SNAT2 mRNA levels in
normoxia and hypoxia in a number of additional human cancer cell
lines derived from different tissues showed that SNAT2 expression is
widely up-regulated after 48 h of hypoxia in many cancer cell types
(SI Appendix, Fig. S2B).
MCF7 ERα+ cells were used for further investigation. To de-
termine whether the 75- to 90-kDa bands represented a glycosylated
isoform of the 56-kDa SNAT2 isoform 1 protein, samples were
deglycosylated with an N-linked glycosidase [peptide:N-glycosidase F
(PNGase F)]. The disappearance of the 75- to 90-kDa bands after
PNGase F treatment indicates that these bands represent the N-
glycosylated form of the molecule (Fig. 2B).
The effect of HIF-1α or HIF-2α depletion by small interfering
RNA (siRNA) during this period of hypoxia (SI Appendix, Fig. S2 C
and D) was studied. Hypoxic induction of SNAT2 mRNA and pro-
tein expression was significantly reduced by HIF-1α siRNA (P <
0.01, n = 3) (SI Appendix, Fig. S2C). The siRNA knockdown was
validated by immunoblots of the expression of both HIF-1α and
HIF-2α, and by measuring the carbonic anhydrase 9 (CA9) protein
levels (HIF-1α–dependent gene) (21) (SI Appendix, Fig. S2D).
To further assess the role of HIF-1α on SNAT2 induction, we used
an MCF7-HIF1α (−/−) cell line generated through clustered regularly
interspaced short palindromic repeats (CRISPR)/Cas9 methodology.
The time course of hypoxic induction of SNAT2 in MCF7 cells by
qPCR and Western blotting peaked at 48 h. The hypoxic induction of
SNAT2 mRNA and protein was significantly reduced in the MCF7-
HIF1α (−/−) (P < 0.01, n = 3) after 48 h of hypoxia (0.1%O2) (Fig. 2 C
and D). The SNAT2 mRNA was reduced by around 2.2-fold at 48 h
(P < 0.001; Fig. 2C), while the glycosylated SNAT2 protein was re-
duced by 3.6-fold at 48 h of hypoxia (SI Appendix, Fig. S2E). There
was no compensatory hyperinduction of HIF-2α, apart from an earlier
peak in MCF7-HIF1α (−/−), which was induced to similar levels in
both cell lines (Fig. 2D).
Fig. 2. SNAT2 is a hypoxia-induced gene and is mainly regulated by HIF-1α. (A) Immunoblot of four breast cancer cell lines from different histotypes showing
the heterogeneity in basal SNAT2 expression and their response to 48 h of hypoxia. (B) N-linked deglycosylation assay using PNGase in MCF7 cell lysate in
normoxia and hypoxia. (C) MCF7 parental and MCF7-HIF1α knockout cells (−/−) were cultured in normoxia (red) or in hypoxia (blue, 0.1% O2) for 8, 24, and
48 h. mRNAs were analyzed by RT-qPCR and normalized to 21% O2. SNAT2 mRNA was normalized to the mean of β-actin and RPL11. Ctrl, control; KO,
knockout. (D) Immunoblot validation in the same experiment described above. β-Actin is shown as a loading control. (E) MCF7 parental and MCF7-HIF1α (−/−)
cells were transfected with scrambled control or siRNAs against HIF-2α (siHIF2α) or treated with PT2779 (HIF-2α inhibitor, 1 μM) and cultured in normoxia (red)
or in hypoxia (blue, 0.1% O2) for 48 h. mRNAs were analyzed by RT-qPCR. SNAT2 mRNA was normalized to the mean of β-actin and RPL11. (F) Immunoblot of
SNAT2, HIF-1α, and HIF-2α in the same experiment described above (E). β-Actin is shown as a loading control. Error bars indicate SD. *P < 0.05 vs. 21% O2,
**P < 0.01 vs. 21% O2, ****P < 0.0001 vs. 21% O2; one-way ANOVA (n = 3 for all experiments).




















Interestingly, HIF-2α depletion by siRNA or by a specific inhibitor
(PT2977, 1 μM) reduced both SNAT2 mRNA and protein hypoxic
induction (0.1% O2) (P = 0.004) (Fig. 2 E and F) in the control cells.
The HIF-2α depletion (siRNA or inhibitor) in MCF7-HIF1α (−/−)
reduced the SNAT2 mRNA induction to the basal levels (although
this was not statistically significant) (Fig. 2 E and F). These data
suggest that HIF-1α is responsible for around 65% of mRNA hyp-
oxic induction of SNAT2 and HIF-2α is responsible for the remaining
35% of induction, but that it does not compensate for the effect
of HIF-1α.
We then stably overexpressed HIF-1α by retroviral vector-mediated
transduction in MCF7 (MCF7-HIF1α-o). Measurement of SNAT2
and CA9 mRNA levels in normoxia showed increased SNAT2 and
CA9 expression in MCF7-HIF1α-o, while no further increase was seen
in hypoxia (SI Appendix, Fig. S2E).
SNAT2 Is Up-Regulated under Hypoxia In Vivo. To determine whether
hypoxic induction of SNAT2 occurs also in solid tumors, two breast
cancer cell lines, MCF-7 and MDA-MB-231, were injected into nude
mice and grown as xenografts. MDA-231 cells were used to assess
the effect of hypoxia independent of ER expression. The mice were
treated with either saline control or the VEGF inhibitor, bev-
acizumab, which slowed tumor growth temporarily (SI Appendix, Fig.
S3 A and B). Treatment with bevacizumab increased SNAT2 protein
levels in both MCF7 and MDA-MB-231 xenografts (P < 0.05; Fig.
3A). Human SNAT2mRNA and CA9mRNA were up-regulated also
(Fig. 3 A and B). Bevacizumab decreased the percentage of blood
vessels (CD31), and, accordingly, the proportion of necrosis (he-
matoxylin/eosin) and the percentage of CA9-positive cells (hypoxia)
were greater in bevacizumab-treated xenografts compared with
phosphate-buffered saline–treated xenografts (SI Appendix, Fig. S3
E and F).
Furthermore, we found that SNAT2 colocalized in both xeno-
grafts in the same areas where CA9 and pimonidazole were expressed
(hypoxic areas) (Fig. 3B and SI Appendix, Fig. S3 E and F). To further
investigate the effect of HIF-1α on SNAT2 expression in vivo, an
orthotopic xenograft tumor was established using MCF7-HIF1α (−/−)
and MCF7-HIF1α-o cells. MCF7-HIF1α (−/−) showed no tumor
growth in nonobese diabetic severe combined immunodeficient
(SCID)-γ (NSG) mice (Fig. 3C), indicating that HIF-2α did not
compensate for the absence of HIF-1α.
HIF-1α overexpression resulted in increased SNAT2 expression
(Fig. 3D).
These data show that SNAT2 is regulated by hypoxia in vivo, as
well as in vitro.
ERα and HIF-1α Bind to Overlapping Sites in the SNAT2 Promoter in
MCF7 Cells but Do Not Act Synergistically. Previous studies showed
that the expression of SNAT2 was increased in ER+ breast cancer
cell lines after 17β-estradiol (E2) stimulation, and an estrogen re-
sponse element was described in the SNAT2 promoter in rat mam-
mary glands during gestation (22, 23). Because SNAT2 was among the
202 genes bound by HIF-1α and ERα (10), we investigated the reg-
ulation of SNAT2 expression by estrogen and hypoxia. Utilizing RNA-
seq and HIF-1α and HIF-2α chromatin immunoprecipitation (ChIP)-
seq data in MCF-7 cells, we confirmed the presence of HIF-binding
site sequences (RCGTG) for both HIF-1α and HIF-2α upstream of
the promoter region of SNAT2 (24) (Fig. 4A). We aligned the ChIP
results of HIF-1α in MCF7 with previous publicly available ERα-seq
ChIP-seq data from the Encyclopedia of DNA Elements (ENCODE)
in the same cell line (25). Both binding sites for HIF-1α and ERα are
overlapping in the genome in cis-regulatory elements, suggesting a
potential interaction between these two transcription factors for SNAT2
induction (Fig. 4A and SI Appendix, Fig. S4A). Interestingly SNAT1,
another system A transporter, showed ERα-binding sites but not HIF-
binding sites (SI Appendix, Fig. S4A).
We decided to investigate if an interaction existed between HIF-
1α and ERα in driving SNAT2 expression. We cultured MCF7 and
T47D cells in normoxia or hypoxia and treated with or without E2.
Estrogen supplementation induced SNAT2 expression in normoxia.
Small additive effects were seen in hypoxia in MCF7, but levels of
ERα protein significantly decreased (Fig. 4B). A similar induction of
SNAT2 under estradiol and hypoxia, but with a different magnitude,
was also seen for T47D cell line.
To evaluate if estradiol and hypoxia might be responsible for
different localization of SNAT2, we examined SNAT2 distribution
using immunofluorescence after hypoxia (0.1% O2) and estradiol
treatment (10 nM). Hypoxia and estradiol resulted in a significant
increase in SNAT2 staining intensity, but none of the treatments
affected its distribution (green) (Fig. 4A and SI Appendix, Fig. S4C).
SNAT2 was located on punctate structures and the plasma mem-
brane (F-actin, red), but the majority was on an intracellular com-
partment, which has been reported to be the trans-Golgi network
(TGN) (26) (Fig. 4C). Time course experiments of estradiol supple-
mentation in MCF7 in normoxia and hypoxia confirmed the estradiol
dependency in normoxia with no significant additive effects in hypoxia
(SI Appendix, Fig. S4D).
ERα and HIF-1α Signaling Regulate SNAT2 Expression Independently.
To further confirm SNAT2 as an ERα- and HIF-1α–dependent gene,
we cultured MCF7 cells for 5 d in charcoal-stripped, phenol-free
Fig. 3. SNAT2 is up-regulated in vivo by hypoxia. (A)
Representative SNAT2 immunostaining in MDA-MB-
231 (first row) and MCF7 (second row) xenografts
treated with phosphate-buffered saline (PBS; n = 5)
or bevacizumab (Beva; n = 5). (Scale bars: 100 μm.)
SNAT2 protein expression quantification by ImageJ
in the same xenografts is shown. N, necrosis. (B)
Representative SNAT2 and CA9 (hypoxia) immunos-
taining in MDA-MB-231 and MCF7 xenografts treated
with bevacizumab, showing colocalization of SNAT2 in
hypoxic areas of the tumors. (Scale bars: 100 μm). (C)
Xenograft growth curves of MCF7 parental (n = 6) and
MCF7-HIF1α KO cells (n = 7). CRTL, control. (D) Repre-
sentative immunohistochemical images of SNAT2
staining in MCF7 parental and MCF7-HIF1α-o xeno-
grafts and a bar chart of scoring. (Scale bars: 100 μm.)
Error bars indicate SD. *P < 0.05, ***P < 0.01; non-
parametric Mann–Whitney test (n = 5 per group).






























Fig. 4. SNAT2 expression is independently modulated by ERα and HIF-1α, and is up-regulated in a tamoxifen-resistant cell line. (A) RNA-seq and ChIP-seq
genome-browser tracks illustrating occupancy of HIF-1α (Top), HIF-2α (Middle), and ERα (Bottom) at the same genomic coordinates on chromosome 12. The
same plots for H3K4me3 are shown. Peaks (red box) represent the areas where transcription factors interact with DNA. (B) Western blotting for SNAT2, ERα,
HIF-1α, and HIF-2 in MCF-7 and T47D cells treated with 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (C)
Confocal microscopy of SNAT2 (green), phalloidin (F-actin, red), and DAPI (blue) in MCF7 in normoxia (N) and hypoxia (H; 0.1% O2) with or without E2
treatment (E; 10 nM) for 24 h. (D) MCF7 cells were grown in a charcoal-stripped, phenol-free medium for 3 d and then incubated with or without fulvestrant
(Fulv; 10 μM) and with or without 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (E) MCF7 control andMCF7-HIF1α-o cells
were treated with or without 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (F) Representative Western blots of
parental (MCF7-par) and MCF7 tamoxifen-resistant cells (MCF7-TamR) cultured in normoxia and hypoxia (0.1% O2) for 48 h. (G) Graph of the effect of MeIAB
(10 mM) treatment on MCF7 and MCF7-TamR spheroid growth. Error bars indicate SD. **P < 0.05, ***P < 0.01; two-way ANOVA (n = 4).




















medium and treated them with E2 with or without fulvestrant
(ICI182780) in normoxia and hypoxia. Fulvestrant treatment abol-
ished estradiol-dependent SNAT2 induction in normoxia, but only a
small effect was seen in hypoxia (Fig. 4E), suggesting a major role for
HIF-1α in this condition.
We then treated the MCF7-HIF1α-o cells with or without estra-
diol in normoxia and hypoxia. SNAT2 was induced in normoxia and
hypoxia in MCF7-HIF1α-o cells. When wild-type cells were supple-
mented with E2, an increase of SNAT2 was seen only in normoxia but
not in hypoxia (Fig. 4E), while in MCF7-HIF1α-o cells, an increased
level of SNAT2 was seen in both conditions, suggesting that HIF1-o
might enhance ER signaling as previously reported (10) (Fig. 4E).
We then evaluated the 202 genes that we have previously shown to
have binding sites for both HIF-1α and ERα (10). Using different
publicly available experiments (24, 25), we confirmed 179 genes with
both HIF-1α– and ERα-binding sites. Only 31 of these genes (31 of 179,
17.3%) had HIF-1α– and ERα-binding sites located in the same genomic
region (SI Appendix, Table S1). By measuring mRNA, we confirmed also
for some of these genes (GAPDH, ALDOA, and NEAT1) the estradiol
dependency in normoxia and the HIF-1α dependency in hypoxia and
resistance to fulvestrant (SI Appendix, Fig. S4D). This list of 31 genes was
selected for general and metabolic pathway enrichment analysis. We
found enrichment in glycolysis, HIF-1α, and Notch pathways (SI Ap-
pendix, Fig. S4E). The most relevant gene ontology process was the
vesicle-transport pathway (SI Appendix, Fig. S4F).
These data collectively demonstrate that SNAT2 induction, as
well other genes, in MCF7 cells is regulated by ERα but becomes
predominantly a HIF-1α–dependent gene under hypoxia, due to a
potential compensation by HIF-1α when ERα is degraded.
SNAT2 Is Increased in a Tamoxifen-Resistant Breast Cancer Cell Line in
Normoxic Conditions. SNAT2 expression was analyzed in the tamoxifen-
resistant MCF7 cell line (MCF7-TamR) (27). SNAT2 protein was
higher in MCF7-TamR cells compared with parental MCF7 cells in
normoxia, but not in hypoxia (Fig. 4F). Thus, they represent a consti-
tutive SNAT2 model, but with expression within the induced range.
When MCF7-TamR cells were grown as a three-dimensional model
(spheroids), an increase in cell growth was seen compared with
MCF7 parental cells. Interestingly, MCF7-TamR cells were more sen-
sitive to a SNAT2 inhibitor [α-(methylamino)isobutyric acid (MeIAB,
10 mM] compared with the parental cells (maximum volume for
MCF7 = 0.56 mm3 vs. 0.35 mm3 for MCF7-TamR; P < 0.001). This
corresponds to a 37.5% decrease in cell growth for MCF7-TamR cells
after MeIAB treatment versus a 21% decrease in cell growth after
MeIAB treatment for parental MCF7 cells (t test, P < 0.001) (Fig. 4G).
SNAT2 Knockdown Sensitizes Breast Cancer Cells to Antiestrogen
Treatment and Decreases Glutamine Consumption, Decreases Mitochondrial
Respiration, and Regulates mTORC1 Signaling. To investigate the role
of SNAT2 in antiestrogen resistance, we knocked down SNAT2 with
a siRNA pool (double transfection). Cells were treated with E2
(10 nM) and/or fulvestrant (10 μg/mL) in normoxia and hypoxia (Fig.
5A). Cell growth was followed over 5 d (SI Appendix, Fig. S5A).
Consistent with their ER positivity, MCF7 cells were dependent on
E2 for their growth in normoxia and sensitive to fulvestrant in normoxia
and hypoxia (Fig. 5A). SNAT2 knockdown reduced cell prolifera-
tion in normoxia, but the inhibitory effect was greater in hypoxia (Fig.
5A). A similar experiment was performed with MCF7 parental and
MCF7-TamR cells (SI Appendix, Fig. S5 B and C). The latter showed
increased growth in both normoxia and hypoxia compared with
MCF7 controls. SNAT2 knockdown reversed the growth advantage
of TamR cell lines compared with controls in both normoxia and
hypoxia. The combination of SNAT2 knockdown and fulvestrant had
a greater effect compared with a single treatment. This effect was
greater in the TamR cells in both normoxia and hypoxia compared
with controls (SI Appendix, Fig. S5C).
We then investigated if reduced proliferation was linked to re-
duced glutamine intake. We found that glutamine consumption was
increased after E2 supplementation in normoxia and decreased after
fulvestrant treatment as previously described (16). Glutamine con-
sumption was also increased under hypoxia, but no effects were seen
with E2 supplementation or fulvestrant treatment in hypoxia. In-
terestingly, SNAT2 knockdown did not decrease glutamine con-
sumption in normoxia, but a clear effect was seen under hypoxia,
with an additive effect when SNAT2 knockdown was combined with
fulvestrant (Fig. 5B). These data indicate that in MCF7 cells,
SNAT2 inhibition sensitizes to hypoxia and antiestrogen treatment
and reduces glutamine uptake.
We used flow-cytometry analysis with the cationic dye JC-1
staining to examine the change in mitochondrial membrane poten-
tial (ΔΨm) following SNAT2 knockdown in normoxia and hypoxia
with or without fulvestrant (Fig. 5C). Fulvestrant, hypoxia, and the
combination had a significant effect, with 8.9 ± 1.6% (P < 0.01), 10.6 ±
1.4%, and 13.4 ± 1.8% (P < 0.001), respectively, of the cells showing a
loss of mitochondrial membrane potential. When SNAT2 knockdown
was performed in hypoxia, 13.3 ± 1.5% of the cells showed a loss of
mitochondrial membrane potential (P < 0.01; Fig. 5C). SNAT2
knockdown after fulvestrant in normoxia (11.1 ± 2.4%) and hypoxia
(16.5 ± 2.0%) decreased the mitochondrial membrane potential com-
pared with fulvestrant alone in the same conditions (#P < 0.05; Fig. 5C).
The effect of SNAT2 knockdown on mitochondria respiration was
measured by the SeaHorse analyzer. SNAT2 knockdown decreased
maximal respiration and ATP production under no-glutamine con-
ditions but not in normal medium or glucose-free medium (SI Ap-
pendix, Fig. S5D). Fulvestrant alone decreased basal and maximal
respiration (P < 0.01) and ATP production (P < 0.05). However,
SNAT2 knockdown after fulvestrant administration had a further
additive effect on reducing maximal respiration (P < 0.01) compared
with fulvestrant alone (Fig. 5D).
We then assessed the SNAT2 knockdown effect on the mTORC1
pathway. SNAT2 depletion reduced the level of phosphorylated
mTOR (p-mTOR) in its downstream targets, p-pS6, and p-p70 (only
in hypoxia), compared with their total protein levels (SI Appendix,
Fig. S5E). These results confirmed the ability of SNAT2, similar to
other AA transporters, to modulate the mTORC1 signaling cascades
(28). Recent research suggested that mTORC1 is also localized at
the level of the TGN and can be activated by specific TGN-AA
transporters (29). We found that SNAT2 was concentrated on the
TGN in MCF7; although most mTOR is localized in the cytoplasm,
some colocalization with the TGN was also observed, raising the
possibility that it might be associated with SNAT2 in this compartment
(SI Appendix, Fig. S5F).
SNAT2 Is Induced by AA Deprivation, and Its Overexpression Promotes
Resistance to Glutamine Starvation, Hypoxia, and Antiestrogen Treatment
In Vitro. To assess if the shortage of specific AAs can up-regulate
SNAT2, we incubated MCF7 cells in the culture medium depleted of
several AAs in normoxia and hypoxia. Depletion of glutamine, serine,
or glycine (SNAT2 substrates) increased SNAT2 expression in normoxia.
Interestingly, when MCF7 cells were incubated under hypoxia, the
SNAT2 up-regulation became more profound and independent of single
AA deprivation (SI Appendix, Fig. S5G).
We investigated the growth inhibition after SNAT2 knockdown
during metabolic stress. SNAT2 knockdown had an effect on MCF7
growth only under hypoxia in full medium but sensitized MCF7 to
glutamine deprivation in two-dimensional growth, particularly under
hypoxia (SI Appendix, Fig. S5H). A small additive effect was also
seen when SNAT2 was knocked down in a glucose-free medium.
We then stably overexpressed SNAT2 by lentiviral vector-mediated
transduction in MCF7 cells (SNAT2-o) (SI Appendix, Fig. S5I). MCF7
SNAT2-o cells were more resistant to fulvestrant in both normoxia
and hypoxia (SI Appendix, Fig. S5L).
Reciprocally, MCF7-SNAT2–overexpressing spheroids grew faster
than their parental controls in full and, particularly, glutamine-deprived
medium (SI Appendix, Fig. S5M). These data indicate that in MCF7,
SNAT2 inhibition sensitizes to glutamine deprivation and increased
expression enhances growth in low-glutamine conditions.
SNAT2 Overexpression Promotes Resistance to Antiangiogenic and
Antiestrogenic Treatment In Vivo. To further assess the role of SNAT2
in resistance to antiestrogen treatment and hypoxia, MCF7 and
MCF7-SNAT2-o cells were grown as xenografts with and without






























bevacizumab or fulvestrant treatment (Fig. 6A). MCF7-SNAT2-o
xenografts grew faster than the empty vector clone (64.9% the growth
rate of the empty vector). Bevacizumab treatment decreased the growth
of empty vector tumors in the first phase, and tumors then became
resistant. Fulvestrant treatment also reduced the xenograft growth rate
(55.4% the growth rate of empty vector control). The SNAT2 expres-
sors grew more rapidly than the controls. The MCF7-SNAT2-o clones
treated with bevacizumab grew significantly faster than MCF7 empty
vector treated with bevacizumab (11.2% the growth rate of treated
empty vector, P = 0.038). More strikingly, MCF7-SNAT2-o clones
treated with fulvestrant became completely resistant to the anti-
endocrine treatment (267% the growth rate of treated empty vector,
P < 0.001). SNAT2-o xenografts, independent of the treatments, had
increased proliferation compared with controls as determined by
Ki67 staining (P < 0.001; SI Appendix, Fig. S6A).
SNAT2 Expression Correlates with Tumor Hypoxia and Is Associated
with Poorer Recurrence-Free Survival in Endocrine-Treated Breast
Cancer Patients. To evaluate the clinical relevance of SNAT2 in
breast cancer, we determined whether tumor SNAT2 expression
levels were correlated with patient prognosis. Using expression data
derived from The Cancer Genome Atlas (TGCA) breast invasive
cohort (30), we categorized patients according to SNAT2 tertile
expression. Kaplan–Meier analysis of overall mortality (Fig. 6B)
revealed that patients with high tumor SNAT2 expression have a
significantly poorer outcome compared with patients with low tumor
SNAT2 expression (for trend, P = 0.034), with a similar pattern seen in
ER+ patients (Fig. 6B). Moreover, analyzing gene expression data
from 2,433 breast cancer patients using the Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC)cohort (31),
we found that SNAT2 mRNA abundance significantly correlated with
the expression of many genes in our previously reported in vivo hyp-
oxia signature (32), as well as with HIF-1α, but not with HIF-2α
(EPAS), and the whole signature itself (SI Appendix, Fig. S6B). In-
terestingly SNAT2 mRNA levels did not correlate with c-Myc copy
number (SI Appendix, Fig. S6C). We used additional expression data
derived from different breast cancer gene array cohorts, and we tested
if the SNAT2 levels correlated with worse outcomes in ER+ patients
treated with all adjuvant endocrine treatments (including aromatase
inhibitors) or tamoxifen only. High SNAT2 expression correlated with
low recurrence-free survival in patients who received endocrine or
tamoxifen treatments (SI Appendix, Fig. S6D). Moreover, when we
looked at the tamoxifen-treated cohort, we found that high SNAT2
levels correlated with worse outcome in tamoxifen-treated luminal B,
but not luminal A, patients (Fig. 6C).
Discussion
Hypoxia is a cause of tumor aggressiveness and resistance to treat-
ments, including endocrine therapy. Although the role of hypoxia
and the HIF-1α transcriptional response in promoting tumor pro-
gression and metastasis is well established (12), the direct contri-
bution of the HIF family to the regulation of AA transporters has
been less studied, apart from LAT1 and glutamate transporters (17).
Here, we describe a mechanism by which hypoxia can produce re-
sistance to antiendocrine therapy, by substituting a glutamine trans-
porter for ERα in regulating the AA transporter SNAT2. We found
that despite the induction of several AA transporters in hypoxia,
SNAT2 expression was key and able to control the growth response to
glutamine and antiestrogen treatment in vitro and markedly so in vivo.
Both main SNAT2 isoforms were hypoxia-regulated. Until now,
the main isoform has been investigated, while the role of other iso-
forms has not been studied. Recently, it has been shown that different
SLC1A5 isoforms are up-regulated and needed for SLC1A5 activity
under AA deprivation (33). Therefore, the role of isoform 2 now re-
quires further investigation.
The maturation of SNAT2 protein and transmembrane localiza-
tion requires its glycosylation (34), which was maintained in hypoxia.
Hypoxia can modulate protein glycosylation, either directly through
enhanced expression of enzymes of the hexosamine pathway such as
O-GlcNAc transferase (OGT) and O-GlcNAcase or indirectly through
the enhancement of glycolysis (35). Moreover, OGT also regulates
HIF-1α proteasomal degradation (36). Hypoxia increases the amounts
of β1-6GlcNAc–branched N-glycans and poly-LacNAc structures (37),
and HIF-1α can also directly promote the transcription of genes for
fucosyltransferase VII, sialyltransferase ST3Gal-I, and uridine 5′-
diphosphate–galactose transporter-1 (38). In this respect, it will be
interesting assessing the role of glycosylation induced by hypoxia on
proteins relevant to cancer metabolism such as SNAT2.
Accumulating data suggest a significant interplay between hypoxia
and estrogen-mediated pathways in breast cancer cells (10, 39). Hypoxia
down-regulates ERα in human breast cancer cells via a proteasome
pathway (39). We found that both HIF-1α and ERα have binding
sites on the same cis-regulatory region of the SNAT2 gene, sug-
gesting that SNAT2 transcription can be regulated by either of these
Fig. 5. SNAT2 knockdown sensitizes MCF7 cells to
fulvestrant treatment in hypoxia and reduces gluta-
mine intake. (A) Total of 105 cells were seeded in
charcoal-stripped medium and treated with or
without E2 (10 nM), fulvestrant (10 μM), and SNAT2
knockdown for 5 d in normoxia (N; red) and hypoxia
(H; blue, 1% O2) (n = 4). Scr, scrambled control. (B)
Glutamine consumption was calculated as reported
from cells grown in the experiment above. (C) De-
termination of mitochondrial membrane potential
in MCF7 cells by JC-1 staining in normoxia and hyp-
oxia (0.1% O2, 48 h) with or without SNAT2 knock-
down and with or without fulvestrant (Fulv; 10 μM).
Values in the trapeziform regions indicate the pro-
portion of cells compared with the total number of
cells. The percentage of depolarized green mito-
chondria is shown in the R2 box. (A–C) *P < 0.05,
**P < 0.01, ***P < 0.001, #P < 0.05 (compared with
Fulv treatment) by χ2 test compared with controls
(n = 3). (D) Representative plot of O2 consumption
with or without SNAT2 knockdown with or without
Fulv (10 μM) in normoxia (21% O2). *P < 0.05, **P <
0.01, #P < 0.05 (compared with Fulv treatment); un-
paired t test (n = 3). Ant, antimycin A; Ctrl, control;
FCCP, carbonyl cyanide-4-(trifluoromethoxy)phenyl-
hydrazone; OCR, oxygen consumption rate; Rot, ro-
tenone.




















two transcription factors, permitting hypoxia-dependent growth un-
der antiestrogen treatment. Of interest was a further set of genes
regulated by ERα in normoxia and by HIF-1α in hypoxia independent
of ERα. These genes warrant further investigation for roles in hormone
independence.
We also found a binding site for HIF-2α in the cis-regulatory re-
gion of SNAT2. HIF-1α and HIF-2α share common targets, including
VEGFA, glucose transporter 1 (GLUT1), and erythropoietin (40).
Both HIF transcription factors have different time courses of in-
duction by hypoxia, with HIF-1α peaking earlier, while the activation
of HIF-2α occurs later (41). Thus, a potential switch from HIF-1α to
HIF-2α has been proposed to maintain the long-term adaptation to
hypoxia (42). Although knockdown of HIF-2α in MCF7 cells showed a
significant reduction of SNAT2 mRNA and protein, suggesting also a
role of HIF-2α in maintaining SNAT2 induction, we did not find any
compensatory induction of HIF-2α in HIF-1α–silenced MCF7 cells in
vitro and in vivo. Similarly, a recent systematic analysis of the pan-
genomic distributions in cancer cells of the two major isoforms of HIF
showed strong support for intrinsically distinct patterns of binding, in
which disruption of either HIF gene had very little effect on the
binding of the other, with little evidence for cross-compensation at
sites that bound both HIF isoforms (43).
Increased glutamine metabolism has been shown to play a role in re-
sistance to medical treatment, including endocrine treatments (44). Lumi-
nal (ER+) breast cancers are more dependent on oxidative phosphorylation
(OXPHOS) than on aerobic glycolysis (45), and the transition from the
Fig. 6. SNAT2 expression is related to poor outcomes in endocrine-treated breast cancer patients. (A) Xenograft growth curves of MCF7 parental and SNAT2-
o clones ± bevacizumab (BEV) or ± fulvestrant (FULV) treatment. CTL, control. ***P < 0.001, **P < 0.01, *P < 0.05; linear regression followed by Student’s
t test (n = 5). (B) Kaplan–Meier plot for patients from the TGCA breast cancer invasive cohort (ALL and ER+ cohorts) stratified according to the expression of
SNAT2 mRNA expression (T1, lower tertile; T2, middle tertile; T3, upper tertile). Overall survival (OS) was evaluated. The graph shows that high tumor SNAT2
levels are associated with increased patient mortality. Subanalysis based on tertile expression showed that the higher SNAT2 mRNA expression (upper tertile)
cohort has a lower survival compared with the lower tertile cohort (T3 vs. T1). HR, hazard ratio. (C) Kaplan–Meier plots for luminal A and B ER+ breast cancer
patients (Left) and for same subgroups that received endocrine [aromatase inhibitor (AI) or tamoxifen (TAM), Center] or tamoxifen only (Right). Patients were
stratified according to the expression of SNAT2 mRNA [above (red) versus below (black) third quartile]. Recurrence-free survival was evaluated.






























sensitivity from antiestrogen treatments to a resistant state is also medi-
ated by the promotion of OXPHOS (46). Our data are in agreement with
a key role of OXPHOS and glutamine consumption, through SNAT2 up-
regulation, in modulating endocrine resistance. Of interest, SNAT2 was
also strongly up-regulated by hypoxia in ER− breast cancer cells; thus, its
role in triple-negative breast cancer, which is generally more hypoxic and
glutamine-dependent (47), deserves further evaluation.
SNAT2 knockdown shifted the mitochondrial membrane poten-
tial in both normoxia and hypoxia, suggesting the decrease in cell
growth might be mediated by mitochondrial impairment. These data
suggest that the dependency on SNAT2 in hypoxia to maintain the
TCA cycle cannot be compensated for by other AA transporters,
which are not induced by hypoxia in breast cancer cells, confirming
recent suggestions that SNAT2 acts as a rescue transporter providing
AA intake under stress conditions (48).
SNAT2 was up-regulated in response to withdrawal of its sub-
strates and also leucine and isoleucine. Interestingly serine with-
drawal (SNAT2 substrate) did not modify SNAT2 protein expression.
ER+ breast cancer cell lines are known to be more susceptible to
serine depletion, probably due to lack of amplification of phospho-
glycerate dehydrogenase, and thus are less addicted to serine metab-
olism compared with ER− tumors (49, 50). We postulate that other
AA transporters, such as ASCT1 (SLC1A4) and ASCT2 (SLC1A5),
might be more important for serine uptake in MCF7 cancer cells.
The xenograft models demonstrated a far more profound effect of
antiestrogen resistance than the in vitro data. Metabolic modifications
are often more profound in vivo because of continuous poor nutrient
conditions and hypoxic, acidic, and glucose gradients. Additionally, SNAT2
expression is tightly controlled at the posttranslational level (51). AA
starvation results in uncharged transfer RNAs, activating GCN2 and
ATF4, which, in turn, will cause translation of the abundant SNAT2
mRNA by a cap-independent mechanism (52). SNAT2 protein is also
degraded after ubiquitination (53), and this may occur under nutrient-
replete conditions, but it is halted when AAs are depleted. This could
explain the more rapid growth rate of SNAT2-overexpressing tumors
and could potentially be related to scavenging glutamine.
A well-known downstream effector of ERα is c-Myc (54). It is up-
regulated by E2, and it plays a critical role in modulating resistance
to endocrine therapies, by the unfolded protein response (UPR), in
ERα+ breast cancer (44, 55). Although SNAT2 is induced by the
UPR (56) and Myc was found to selectively bind to the promoter
regions of SNAT2 (57), we did not find any correlation between c-Myc
copy number and SNAT2 mRNA levels in breast cancer patients.
Finally, our analysis of clinical data available from large RNA expression
cohorts suggests that high baseline SNAT2 expression correlates with poor
survival in patients with breast cancer and with reduced recurrence-free
survival in ER+ endocrine-treated breast cancer patients, specifically in the
luminal B subtype (ER+ subtype). The luminal B subtype has aggressive
clinical behavior, with a prognosis similar to that of the HER2-enriched and
basal-like groups and a lower sensitivity to endocrine treatment compared
with luminal A ER+ breast cancer (58). Recent studies showed that high
expression of different AA transporters, such as SLC3A2 or SLC7A5, is
related to poor outcomes in the luminal B ER+ breast cancer subtype
(59), suggesting that this subtype might be particularly vulnerable to
glutamine depletion. Clinical selection may be possible, as an AA-based
positron emission tomography radiotracer, 18F-fluciclovine, has recently
been investigated in the imaging of breast cancer (60).
As targeting glutamine metabolism is the subject of intensive re-
search due to its potential clinical applications (14), we propose that
SNAT2 should be investigated as a predictive biomarker and a po-
tential target for well-defined molecular subtypes (luminal B) of ER+
breast cancer patients and as a combination approach to overcome
endocrine therapy resistance.
Materials and Methods
RNA-Seq and Bioinformatics. RNA-seq was performed as previously described
(24). The sequenced paired-end reads were aligned to human reference
genome GRCh38 with transcriptomic information of the genome by Bowtie
2.2.6 and Tophat v2.1. We then estimated the fold changes on the normalized
expression level (fragments per kilobase of transcript per million mapped
reads) for each gene and its transcriptional isoforms from those mapped reads
using Cuffdiff 2.2.1. The means and SDs are calculated over the triplicates of
each cell line. ChIP-seq databases were analyzed as previously described (40).
For heatmap and hierarchical clustering, supervised exploratory analysis,
transcriptomic data were standardized on a z-score scale. K-mean was utilized
to determine the optimal number of clusters. Survival analysis of the TGCA and
gene arrays dataset (GSE12093, GSE16391, GSE17705, GSE19615, GSE26971,
GSE2990, GSE3494, GSE37946, GSE45255, GSE6532, and GSE9195) cohorts was
performed in an R statistical environment (v3.3.2) using survival package (v2.41-3).
Xenograft Studies. Procedures were carried out after the approval by the
institutional review board at the University of Oxford and under a Home
Office license. Xenograft experiments were performed in female BALB/c nu/
nu (MCF-7 cells) and BALB/c SCID (MDA-MB-231) mice. A total of 2.5 × 106
(MCF-7) cells or 10 × 106 (MDA-MB-231) cells were injected subcutaneously
(s.c.) in the lower flank. Mice injected with MCF-7 cells had estrogen (5 μg/mL)
added to their drinking water. Once tumors reached 150 mm3, the BALB/c nu/
nu (MCF-7 cells) and BALB/c SCID (MDA-MB-231) mice received either in-
traperitoneal (i.p.) bevacizumab (10 mg/kg every 3 d) or vehicle control. For
MCF7 ± HIF-1α-o or HIF-1α (−/−) xenografts, 50 μL of Matrigel containing 5 ×
106 MCF7 ± HIF-1α-o (14) or 106 MCF7 ± HIF-1α-o HIF-1α (−/−) was implanted
into the mammary fat pad of NSG female mice, aged 5–6 wk, implanted with
an estrogen pellet (0.72 mg, 90-d release). When tumors reached 1.44 cm3,
mice were killed by cervical dislocation (3). For MCF7 parental and MCF7
SNAT2-o experiments, 5 × 106 cells were injected s.c. in the lower flank.
Bevacizumab (10 mg/kg) was injected i.p. every 3 d, and fulvestrant (100 mg/
kg) was injected from day 15 until death. All xenografts were also implanted
with estrogen as seen above. Tumor growth was monitored three times per
week measuring the length (L), width (W), and height (H) of each tumor using
calipers. Volumes were calculated from the equation 1/6 × π × L × W × H.
Statistical Analysis. Statistical analysis was performed and graphs were con-
structed using GraphPad Prism v6.0. Results are plotted as mean values with
SD. Statistical tests and the number of repeats are described in the figure
legends. The Student’s t test was used for two-sample analyses, and normal
distributions were assumed; otherwise, the nonparametric Mann–Whitney
test was used. Analysis of variance was used for more than two-sample
analyses. Linear regression of log-transformed growth data was used for
the xenograft experiments. No samples or experimental repeats were ex-
cluded from analyses. No statistical methods were used for the sample size
selection of other experiments.
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